Results 91 to 100 of about 3,081 (193)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and ...
László, Tamás, Bátai, Bence, Tárkányi, Ilona, Rottek, János, Molnár, Zsuzsa, Illés, Árpád, Bödör, Csaba, Szász, Róbert, Varga, Luca, Rajnics, Péter, Alpár, Donát, Pinczés, László, Gulyás, Anita, Timár, Botond, Nagy, Zsolt, Egyed, Miklós, Tamáska, Péter, Plander, Márk, Magyari, Ferenc, Masszi, András   +19 more
core  

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia

eJHaem
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman, Michael Choi, Thomas J. Kipps   +2 more
doaj   +1 more source

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia : A Consensus Report by Hematologists and Cardiologists

Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton's tyrosine kinase inhibitors (BTKis).
Slanina Miroslav, Munir Talha, Gospodinova Mariana, Petríková Lucia, Pozsonyi Zoltan, Lipar Luka, Graklanov Vasko, Škerget Matevž, Jakšić Ozren, Panovská Anna, Pileckyte Regina, Marton Imelda, Bulj Nikola, Čiburienė Eglė   +13 more
core   +1 more source

Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways

Annals of Hematology
It is widely acknowledged that B-cell lymphoma represent a significant threat to human health, and Bruton Tyrosine Kinase inhibitors (BTKi) have been shown to exhibit superior clinical efficacy and safety in comparison to conventional chemotherapy and ...
Xinyu Dong, Shujun Tang, Miaohong Chen, Qiuni Chen, Yifan Wang, Yuye Shi, Yuan Deng, Yue Chen, Zhengmei He, Liang Yu, Chunling Wang   +10 more
doaj   +1 more source

Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

Cancers
Background: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKis) for central nervous system lymphoma (CNSL). Methods: A systematic review was carried out to identify relevant studies from the PubMed, Embase, Cochrane Library, Web of Science, WanFang, CNKI, and CBM databases. The
Yan Zhang, Jingjing Ye, Hao Chen, Daobin Zhou, Chunyan Ji   +4 more
openaire   +2 more sources

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

HemaSphere, 2023
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Marina Motta, Marina Deodato, Elisa Bossi, Veronica Mattiello, Maria Beatrice Ferrari, Giulia Cotilli, Carlo Gambacorti-Passerini, Roberto Cairoli, Massimo Puoti, Alessandra Tedeschi   +14 more
openaire   +3 more sources

DP055 | DISTINCT RELAPSE PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA AFTER THERAPY WITH BTK OR BCL2 INHIBITORS

Haematologica
Introduction Bruton tyrosine kinase inhibitors (BTKi) and venetoclax exert their effect on two different populations of chronic lymphocytic leukemia (CLL) cells: while BTKi act on the dividing subpopulation of CLL cells, which is killed after ...
F. Angotzi, A. Cellini, A. Serafin, C.A. Cavarretta, V. Ruocco, A. Bevilacqua, N. Danesin, G. Leone, L. Trentin, A. Visentin.   +9 more
doaj  

Efficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review

Cancer Medicine
Background Bruton's tyrosine kinase inhibitors (BTKi) and the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL).
Mohammed Zuber, Sreelatha Akkala, Niying Li, Sajesh K. Veettil, Chia Jie Tan, Lorenzo Villa Zapata   +5 more
doaj   +1 more source

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy.

, 2020
PURPOSE: Venetoclax-based therapy is a standard of care option in front-line and relapsed/refractory CLL. Patient management following venetoclax discontinuation remains non-standard and poorly understood.
Eyre, Toby A, Pagel, John M, Goodfriend, Julie M, Allan, John N, Shadman, Mazyar, Hill, Brian T, Roeker, Lindsey E, Coombs, Catherine C, Khajavian, Sirin, Fakhri, Bita, Whitaker, Kate J, Shah, Pratik, Voorhees, Timothy J, Bigelow, Kayla, Skarbnik, Alan P, Garcia, Christine A, Barrientos, Jacqueline, Akhtar, Othman S, Lee, Jason C, Dorsey, Colleen, Fox, Christopher P, Pocock, Rachael, Pinilla-Ibarz, Javier A, Ujjani, Chaitra S, Schuster, Stephen J, Bhavsar, Erica B, Portell, Craig A, Gohil, Satyen, Bailey, Neil, Torka, Pallawi, Munir, Talha, Lam, Kentson, Weissbrot, Hanna B, Isaac, Krista M, Barr, Paul M, Parry, Helen, Rodgers, Thomas D, King, Amber C, Nabhan, Chadi, Sitlinger, Andrea, Lamanna, Nicole, Perini, Guilherme Fleury, Pu, Jeffrey J, Zelenetz, Andrew D, Choi, Michael, Sarraf Yazdy, Maryam, Winter, Allison M, Cheson, Bruce D, Mato, Anthony R, Jacobs, Ryan, Brander, Danielle, Rhodes, Joanna, Martinez-Calle, Nicolas, Grajales-Cruz, Ariel F   +53 more
core